Biotechnology stocks, especially those issued by smaller, less-seasoned companies, tend to be more volatile than the overall market
Split dosing adds complexity
selection should consider presence of cardiovascular disease, heart failure, or chronic kidney disease DPP-4 inhibitors (such as sitagliptin or linagliptin) oral agents with a different mechanism Insulin therapy particularly if glycaemic control is inadequate with oral agents Pioglitazone may be appropriate in selected patients without heart failure Sulfonylureas (such as gliclazide) though associated with hypoglycaemia and weight gain Your diabetes specialist or GP will conduct a comprehensive review of your treatment plan, considering factors such as HbA1c targets, cardiovascular risk profile, renal function, and personal preferences
When any component of this system becomes damaged, inflamed, or degenerative, the resulting pain can range from mild discomfort to debilitating agony that affects every aspect of daily life
